The FDA-approved drug label for chloroquine (Aralan) states caution should be taken when administering treatment to G6PD deficient individuals due to the possibility of hematological effects. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.
Excerpt from the chloroquine drug label:
Hematological Effects/Laboratory Tests
Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Chloroquine drug label.
*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.